Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening

Article metrics

Abstract

Purpose

Noninvasive prenatal screening (NIPS) using genome sequencing also reveals maternal copy-number variations (CNVs). Those CNVs can be clinically actionable or harmful to the fetus if inherited. CNVs in the DMD gene potentially causing dystrophinopathies are among the most commonly observed maternal CNVs. We present our experience with maternal DMD gene CNVs detected by NIPS.

Methods

We analyzed the data of maternal CNVs detected in the DMD gene revealed by NIPS.

Results

Of 26,123 NIPS analyses, 16 maternal CNVs in the DMD gene were detected (1/1632 pregnant women). Variant classification regarding pathogenicity and phenotypic severity was based on public databases, segregation analysis in the family, and prediction of the effect on the reading frame. Ten CNVs were classified as pathogenic, four as benign, and two remained unclassified.

Conclusion

NIPS leverages CNV screening in the general population of pregnant women. We implemented a strategy for the interpretation and the return of maternal CNVs in the DMD gene detected by NIPS.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Bianchi DW, Chiu RWK. Sequencing of circulating cell-free DNA during pregnancy. N Engl J Med. 2018;379:464–473.

  2. 2.

    Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370:799–808.

  3. 3.

    Brison N, Neofytou M, Dehaspe L, Bayindir B, Van Den Bogaert K, Dardour L, et al. Predicting fetoplacental chromosomal mosaicism during noninvasive prenatal testing. Prenat Diagn. 2018;38:258–266.

  4. 4.

    Lefkowitz RB, Tynan JA, Liu T, Wu Y, Mazloom AR, Almasri E, et al. Clinical validation of a noninvasive prenatal test for genome-wide detection of fetal copy number variants. Am J Obstet Gynecol. 2016;215:227.e1–227.e16.

  5. 5.

    Li R, Wan J, Zhang Y, Fu F, Ou Y, Jing X, et al. Detection of fetal copy number variants by noninvasive prenatal testing for common aneuploidies. Ultrasound Obstet Gynecol. 2016;47:53–57.

  6. 6.

    Brison N, Van Den Bogaert K, Dehaspe L, et al. Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. Genet Med. 2017;19:306–313.

  7. 7.

    Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 2015;1:814–819.

  8. 8.

    Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA. 2015;314:162–169.

  9. 9.

    Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000 Sep 5 [updated 2018]. In: Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2018. http://www.ncbi.nlm.nih.gov/books/NBK1119/.

  10. 10.

    Landfeldt E, Lindgren P, Bell C, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83:529–536.

  11. 11.

    Ferlini Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord. 1999;9:339–346.

  12. 12.

    Ishizaki M, Kobayashi M, Adachi K, et al. Female dystrophinopathy: review of current literature. Neuromuscul Disord. 2018;28:572–581.

  13. 13.

    Aartsma-Rus A, Van Deutekom JC, Fokkema IF, et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34:135–144.

  14. 14.

    Tuffery-Giraud S, Béroud C, Leturcq F, et al. Genotype-phenotype analysis in 2405 patients with a dystrophinopathy using the UMD-DMD database. A model of nationwide knowledgebase. Hum Mutat. 2009;30:934–945.

  15. 15.

    Belgian Advisory Committee on Bioethics. Opinion no. 66—noninvasive prenatal testing (NIPT). https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/opinion_66_web_1.pdf. Accessed 9 May 2016.

  16. 16.

    Belgian Society for Human Genetics. Belgian guidelines for managing incidental findings detected by NIPT. 2017. http://www.beshg.be/index.php?page=guidelines.

  17. 17.

    Bayindir B, Dehaspe L, Brison N, et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur J Hum Genet. 2015;23:1286–1293.

  18. 18.

    Brady P, Brison N, Van Den Bogaert K, et al. Clinical implementation of NIPT—technical and biological challenges. Clin Genet. 2016;89:523–530.

  19. 19.

    Nguyen K, Putoux A, Busa T, et al. Incidental findings on array comparative genomic hybridization: detection of carrier females of dystrophinopathy without any family history. Clin Genet. 2015;87:488–491.

  20. 20.

    Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet. 2016;53:145–151.

  21. 21.

    Shen JJ, Zhang NR. Change-point model on nonhomogeneous Poisson processes with application in copy number profiling by next-generation DNA sequencing. Ann Appl Stat. 2012;6:476–496.

Download references

Author information

Correspondence to Kris Van Den Bogaert PhD.

Ethics declarations

Disclosure

The authors declare no conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • maternal CNV
  • DMD gene
  • secondary findings
  • NIPS